Robert Niven
- A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthmaBy Edward Piper, Christopher Brightling, Robert Niven, Chad Oh, Raffaella Faggioni, Kwai Poon, Dewei She, Chris Kell, Richard D. May, Gregory P. Geba and Nestor A. MolfinoEdward Piper*MedImmune Ltd, CambridgeChristopher Brightling#Institute of Lung Health, University of Leicester, LeicesterRobert Niven¶University of Manchester and University Hospital of South Manchester, Manchester, UKChad Oh+MedImmune, LLC, Gaithersburg, MDRaffaella Faggioni§MedImmune, LLC, Hayward, CA, USAKwai Poon*MedImmune Ltd, CambridgeDewei She+MedImmune, LLC, Gaithersburg, MDChris Kell*MedImmune Ltd, CambridgeRichard D. May*MedImmune Ltd, CambridgeGregory P. Geba+MedImmune, LLC, Gaithersburg, MDNestor A. Molfino+MedImmune, LLC, Gaithersburg, MD
- The APEX study: A retrospective review of responses of severe allergic asthma patients to omalizumab on continuous or non-continuous oral corticosteroids in UK clinical practiceBy Robert Niven and Amr RadwanRobert Niven1North West Lung Centre, Wythenshawe Hospital, Manchester, United KingdomAmr Radwan2Clinical Development & Medical Affairs, Novartis Pharmaceuticals UK Limited, Frimley/Camberley, Surrey, United Kingdom
- Safety of bronchial thermoplasty out to 5 years in patients with severe refractory asthma: Research in severe asthma (RISA) trialBy Michel Laviolette, Ian Pavord, Neil Thomson, Robert Niven, Gerard Cox, Paul Corris and Kian Fan-ChungMichel LavioletteDépartement de Pneumologie et de Chirurgie Thoracique, IUCPQ, Québec, QC, Canada Department of Respiratory Medicine and Thoracic Surgery, University of Leicester, Leicester, United Kingdom Division of Immunology, Infection & Inflammation, University of Glasgow, Glasgow, United Kingdom Respiratory Medicine, University of Manchester, Manchester, United Kingdom Department of Medicine, McMaster University, Hamilton, ON, Canada Department of Respiratory Medicine, Freeman Hospital, Newcastle-upon-Tyne, United Kingdom Respiratory Medicine, Imperial College London, London, United KingdomIan PavordDépartement de Pneumologie et de Chirurgie Thoracique, IUCPQ, Québec, QC, Canada Department of Respiratory Medicine and Thoracic Surgery, University of Leicester, Leicester, United Kingdom Division of Immunology, Infection & Inflammation, University of Glasgow, Glasgow, United Kingdom Respiratory Medicine, University of Manchester, Manchester, United Kingdom Department of Medicine, McMaster University, Hamilton, ON, Canada Department of Respiratory Medicine, Freeman Hospital, Newcastle-upon-Tyne, United Kingdom Respiratory Medicine, Imperial College London, London, United KingdomNeil ThomsonDépartement de Pneumologie et de Chirurgie Thoracique, IUCPQ, Québec, QC, Canada Department of Respiratory Medicine and Thoracic Surgery, University of Leicester, Leicester, United Kingdom Division of Immunology, Infection & Inflammation, University of Glasgow, Glasgow, United Kingdom Respiratory Medicine, University of Manchester, Manchester, United Kingdom Department of Medicine, McMaster University, Hamilton, ON, Canada Department of Respiratory Medicine, Freeman Hospital, Newcastle-upon-Tyne, United Kingdom Respiratory Medicine, Imperial College London, London, United KingdomRobert NivenDépartement de Pneumologie et de Chirurgie Thoracique, IUCPQ, Québec, QC, Canada Department of Respiratory Medicine and Thoracic Surgery, University of Leicester, Leicester, United Kingdom Division of Immunology, Infection & Inflammation, University of Glasgow, Glasgow, United Kingdom Respiratory Medicine, University of Manchester, Manchester, United Kingdom Department of Medicine, McMaster University, Hamilton, ON, Canada Department of Respiratory Medicine, Freeman Hospital, Newcastle-upon-Tyne, United Kingdom Respiratory Medicine, Imperial College London, London, United KingdomGerard CoxDépartement de Pneumologie et de Chirurgie Thoracique, IUCPQ, Québec, QC, Canada Department of Respiratory Medicine and Thoracic Surgery, University of Leicester, Leicester, United Kingdom Division of Immunology, Infection & Inflammation, University of Glasgow, Glasgow, United Kingdom Respiratory Medicine, University of Manchester, Manchester, United Kingdom Department of Medicine, McMaster University, Hamilton, ON, Canada Department of Respiratory Medicine, Freeman Hospital, Newcastle-upon-Tyne, United Kingdom Respiratory Medicine, Imperial College London, London, United KingdomPaul CorrisDépartement de Pneumologie et de Chirurgie Thoracique, IUCPQ, Québec, QC, Canada Department of Respiratory Medicine and Thoracic Surgery, University of Leicester, Leicester, United Kingdom Division of Immunology, Infection & Inflammation, University of Glasgow, Glasgow, United Kingdom Respiratory Medicine, University of Manchester, Manchester, United Kingdom Department of Medicine, McMaster University, Hamilton, ON, Canada Department of Respiratory Medicine, Freeman Hospital, Newcastle-upon-Tyne, United Kingdom Respiratory Medicine, Imperial College London, London, United KingdomKian Fan-ChungDépartement de Pneumologie et de Chirurgie Thoracique, IUCPQ, Québec, QC, Canada Department of Respiratory Medicine and Thoracic Surgery, University of Leicester, Leicester, United Kingdom Division of Immunology, Infection & Inflammation, University of Glasgow, Glasgow, United Kingdom Respiratory Medicine, University of Manchester, Manchester, United Kingdom Department of Medicine, McMaster University, Hamilton, ON, Canada Department of Respiratory Medicine, Freeman Hospital, Newcastle-upon-Tyne, United Kingdom Respiratory Medicine, Imperial College London, London, United Kingdom
- Phase 2 randomized, double-blind, placebo-controlled study of tralokinumab, an anti-IL-13 monoclonal antibody, in moderate to severe asthmaBy Edward Piper, Christopher Brightling, Robert Niven, Chad Oh, Raffaella Faggioni, Kwai Poon, Dewei She, Chris Kell, Richard May, Gregory Geba and Nestor MolfinoEdward Piper1Clinical Development, MedImmune, Gaithersburg, MD, United StatesChristopher Brightling2Institute of Lung Health, University of Leicester, Leicester, United KingdomRobert Niven3University Hospital of South Manchester, University of Manchester, Manchester, United KingdomChad Oh1Clinical Development, MedImmune, Gaithersburg, MD, United StatesRaffaella Faggioni1Clinical Development, MedImmune, Gaithersburg, MD, United StatesKwai Poon1Clinical Development, MedImmune, Gaithersburg, MD, United StatesDewei She1Clinical Development, MedImmune, Gaithersburg, MD, United StatesChris Kell1Clinical Development, MedImmune, Gaithersburg, MD, United StatesRichard May1Clinical Development, MedImmune, Gaithersburg, MD, United StatesGregory Geba4Formerly with Clinical Development, MedImmune, Gaithersburg, MD, United StatesNestor Molfino1Clinical Development, MedImmune, Gaithersburg, MD, United States
- BTS Difficult Asthma Registry: Effect of omalizumab dosing table expansion on size of population of severe persistent allergic asthma patients potentially eligible for omalizumab therapyBy Liam Heaney, Andrew Menzies-Gow, Adel Mansur, Chris Brightling, Robert Niven, Rekha Chaudhuri, Christine Bucknall and Amr RadwanLiam Heaney1Centre for Infection and Immunity, Queen's University of Belfast, United KingdomAndrew Menzies-Gow2Asthma and Allergy, Royal Brompton Hospital, London, United KingdomAdel Mansur3Respiratory Medicine, Birmingham Heartlands NHS Trust, Birmingham, United KingdomChris Brightling4Institute for Lung Health, University of Leicester, United KingdomRobert Niven5Respiratory Medicine, University of Manchester and University Hospital of South Manchester, United KingdomRekha Chaudhuri6Respiratory Medicine, Gartnavel General Hospital, Glasgow, United KingdomChristine Bucknall7Respiratory Medicine, Glasgow Royal Infirmary, Glasgow, United KingdomAmr Radwan8Respiratory Medicine, Novartis Pharmaceuticals UK Limited, Frimley/Camberley, Surrey, United Kingdom
- Improvement in asthma severity and control by voriconazole and posaconazole in severe asthma with fungal sensitization (SAFS) and ABPABy Livingstone Chishimba, Robert Niven and David DenningLivingstone Chishimba1North West Lung Centre, University Hospital of South Manchester, Manchester, United Kingdom2Respiratory Research Group, Manchester Academic Health Science Centre, University of South Manchester, Manchester, United KingdomRobert Niven1North West Lung Centre, University Hospital of South Manchester, Manchester, United Kingdom2Respiratory Research Group, Manchester Academic Health Science Centre, University of South Manchester, Manchester, United KingdomDavid Denning1North West Lung Centre, University Hospital of South Manchester, Manchester, United Kingdom2Respiratory Research Group, Manchester Academic Health Science Centre, University of South Manchester, Manchester, United Kingdom
- Pulmonary response to salbutamol inhalation using dynamic OE-MRI in patients with asthmaBy Weijuan Zhang, Robert Niven, Simon Young, Yuzhen Liu, Geoffrey Parker and Josephine NaishWeijuan Zhang1Centre of Imaging Sciences, The University of Manchester, Manchester, United Kingdom2Biomedical Imaging Institute, The University of Manchester, Manchester, United KingdomRobert Niven3The North West Lung Centre, University Hospital of South Manchester, Manchester, United Kingdom4Department of Respiratory Medicine, University Hospital of South Manchester, Manchester, United KingdomSimon Young5Personalised Healthcare and Biomarkers, AstraZeneca, Alderley Park, United KingdomYuzhen Liu5Personalised Healthcare and Biomarkers, AstraZeneca, Alderley Park, United KingdomGeoffrey Parker1Centre of Imaging Sciences, The University of Manchester, Manchester, United Kingdom2Biomedical Imaging Institute, The University of Manchester, Manchester, United Kingdom6BiOxyDyn Limited, BiOxyDyn Limited, Manchester, United KingdomJosephine Naish1Centre of Imaging Sciences, The University of Manchester, Manchester, United Kingdom2Biomedical Imaging Institute, The University of Manchester, Manchester, United Kingdom
- Feasibility and acceptability of group-CBT for people with severe asthmaBy Janelle Yorke, Sharon Fleming, Caroline Shuldham, Anne-Marie Doyle, Andrew Menzies-Gow, Pauline Adair, Linda Dubrow-Marshall, Ann Caress and Robert NivenJanelle Yorke1School of Nursing, Midwifery and Social Work, Universty of Manchester, Manchester, United KingdomSharon Fleming2Nursing Research and Quality, Royal Brompton and Harefield NHS Foundation Trust, London, United KingdomCaroline Shuldham2Nursing Research and Quality, Royal Brompton and Harefield NHS Foundation Trust, London, United KingdomAnne-Marie Doyle3Psychological Services, Royal Brompton and Harefield NHS Foundation Trust, London, United KingdomAndrew Menzies-Gow4Respiratory Medicine, Royal Brompton and Harefield NHS Foundation Trust, London, United KingdomPauline Adair5College of Health and Social Care, University of Salford, Salford, United KingdomLinda Dubrow-Marshall5College of Health and Social Care, University of Salford, Salford, United KingdomAnn Caress1School of Nursing, Midwifery and Social Work, Universty of Manchester, Manchester, United KingdomRobert Niven6Respiratory Medicine, University Hospital of South Manchester, Manchester, United Kingdom
- Using induced sputum cell counts to guide management of difficult-to-treat asthmaticsBy Mithun Murthy, Julie Scanlan, Robert Niven and Stephen ScottMithun Murthy1Respiratory Medicine, Countess of Chester Hospital, Chester, United KingdomJulie Scanlan1Respiratory Medicine, Countess of Chester Hospital, Chester, United KingdomRobert Niven1Respiratory Medicine, Countess of Chester Hospital, Chester, United KingdomStephen Scott1Respiratory Medicine, Countess of Chester Hospital, Chester, United Kingdom
- A phase 2 placebo-controlled study of tralokinumab in moderate-to-severe asthmaBy Edward Piper, Christopher Brightling, Robert Niven, Chad Oh, Raffaella Faggioni, Kwai Poon, Dewei She, Chris Kell, Richard D May, Gregory P. Geba and Nestor A MolfinoArticle | Published in 2012 in European Respiratory JournalEdward PiperChristopher BrightlingRobert NivenChad OhRaffaella FaggioniKwai PoonDewei SheChris KellRichard D MayGregory P. GebaNestor A Molfino
- Quantitative dynamic contrast-enhanced MRI of the lung in asthmaBy Wei-juan Zhang, Robert Niven, Simon Young, Yu-zhen Liu, Geoffrey Parker and Josephine NaishWei-juan Zhang1Centre for Imaging Sciences, University of Manchester, Manchester, United Kingdom2BioMedical Imaging Institute, University of Manchester, Manchester, United KingdomRobert Niven3North West Lung Research Centre, University Hospital of South Manchester, Manchester, United KingdomSimon Young4Personalised Healthcare and Biomarkers, AstraZeneca R&D, Alderley Park, United KingdomYu-zhen Liu4Personalised Healthcare and Biomarkers, AstraZeneca R&D, Alderley Park, United KingdomGeoffrey Parker1Centre for Imaging Sciences, University of Manchester, Manchester, United Kingdom2BioMedical Imaging Institute, University of Manchester, Manchester, United Kingdom5Bioxydyn Limited, Bioxydyn Limited, Manchester, United KingdomJosephine Naish1Centre for Imaging Sciences, University of Manchester, Manchester, United Kingdom2BioMedical Imaging Institute, University of Manchester, Manchester, United Kingdom5Bioxydyn Limited, Bioxydyn Limited, Manchester, United Kingdom
- Dysfunctional breathing patterns: A literature review and proposal for classificationBy Richard Boulding, Robert Niven and Stephen FowlerRichard Boulding1Medicine, Lancashire Teaching Hospitals NHS Foundation Trust, Preston, United KingdomRobert Niven2Respiratory and Allergy Clinical Research Facility, University Hospital South Manchester NHS Foundation Trust, Manchester, United Kingdom3Institute of Inflammation and Repair, University of Manchester, Manchester, United KingdomStephen Fowler1Medicine, Lancashire Teaching Hospitals NHS Foundation Trust, Preston, United Kingdom2Respiratory and Allergy Clinical Research Facility, University Hospital South Manchester NHS Foundation Trust, Manchester, United Kingdom3Institute of Inflammation and Repair, University of Manchester, Manchester, United Kingdom
- Indirect comparison of bronchial thermoplasty (BT) versus omalizumab (OM) for severe uncontrolled asthmaBy Robert Niven, Michael Simmonds, Michael Cangelosi, Narinder Shargill, Dominic Tilden and Suzanne CottrellRobert Niven1North West Lung Research Center, University of Manchester & University Hospital of South Manchester, Manchester, United KingdomMichael Simmonds2Health Economics & Government Affairs, Boston Scientific Corporation, Sydney, AustraliaMichael Cangelosi3Health Economics and Reimbursement, Boston Scientific Corporation, Marlborough, MA United StatesNarinder Shargill4Clinical Affairs, Boston Scientific Corporation, San Jose, CA United StatesDominic Tilden5Health Economics, THEMA Consulting, Sydney, AustraliaSuzanne Cottrell5Health Economics, THEMA Consulting, Sydney, Australia
- IL-17A in severe asthma, severe asthma with fungal sensitisation and ABPABy Livingstone Chishimba, Robert Niven, Marcin Fraczec, Angela Simpson, Paul Bowyer and David DenningLivingstone Chishimba1Respiratory Research Group, University of Manchester, Manchester, United Kingdom3Respiratory Medicine, University Hospital of Wales, Cardiff, United KingdomRobert Niven2Respiratory Medicine, University Hospital of South Manchester, Manchester, United KingdomMarcin Fraczec1Respiratory Research Group, University of Manchester, Manchester, United KingdomAngela Simpson1Respiratory Research Group, University of Manchester, Manchester, United KingdomPaul Bowyer1Respiratory Research Group, University of Manchester, Manchester, United KingdomDavid Denning1Respiratory Research Group, University of Manchester, Manchester, United Kingdom
- Lung microbiome is associated with asthma severity in fungal associated asthmaBy Livingstone Chishimba, Robert Niven, Marcin Fraczek, Paul Bowyer, Lucy Smyth, Angela Simpson and David DenningLivingstone Chishimba1Respiratory, Inflammation and Allergy, University of Manchester, University Hospital of South Manchester, Manchester, United Kingdom4Respiratory Medicine, University Hospital of Wales (UHW), Cardiff, United KingdomRobert Niven2Respiratory Medicine, University Hospital of South Manchester, Manchester, United KingdomMarcin Fraczek1Respiratory, Inflammation and Allergy, University of Manchester, University Hospital of South Manchester, Manchester, United KingdomPaul Bowyer1Respiratory, Inflammation and Allergy, University of Manchester, University Hospital of South Manchester, Manchester, United KingdomLucy Smyth3Aiway Immunology, University of Salford, Manchester, United KingdomAngela Simpson1Respiratory, Inflammation and Allergy, University of Manchester, University Hospital of South Manchester, Manchester, United KingdomDavid Denning1Respiratory, Inflammation and Allergy, University of Manchester, University Hospital of South Manchester, Manchester, United Kingdom
Buying books on this site
Purchases made on this website are of electronic books only.
About the ERS books
The ERS Monograph is the quarterly book series from the European Respiratory Society. Each Monograph covers a specific area of respiratory medicine, providing in-depth reviews that give clinicians at all levels a concise, comprehensive guide to symptoms, diagnosis and treatment.
The ERS Handbooks are compact guides to broad areas of the respiratory field. Launched in 2010, the series now covers adult, paediatric and sleep respiratory medicine, includes a companion volume of self-assessment questions and features the ERS Practical Handbooks.